Mobility in a Globalised World 2012

The term mobility has different meanings in the following science disciplines. In economics, mobility is the ability of an individual or a group to improve their economic status in relation to income and wealth within their lifetime or between generations. In information systems and computer science, mobility is used for the concept of mobile computing, in which a computer is transported by a person during normal use. By designing logistics networks, logistics creates the infrastructure for the mobility of people and goods. Electric mobility is one of today’s solutions from an engineering perspective to the problem of reducing the need for energy resources and environmental impact. Finally, for urban planning, mobility is the crunch question as to how to optimise the different needs for mobility and how to link different transportation systems. In this publication we have collected the ideas of practitioners, researchers, and government officials about the different modes of mobility in a globalised world, focusing on both domestic and international issues

Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure

The first-in-class soluble guanylate cyclase (sGC) stimulator riociguat was recently introduced as a novel treatment option for pulmonary hypertension. Despite its outstanding pharmacological profile, application of riociguat in other cardiovascular indications is limited by its short half-life, necessitating a three times daily dosing regimen. In our efforts to further optimize the compound class, we have uncovered interesting structure–activity relationships and were able to decrease oxidative metabolism significantly. These studies resulting in the discovery of once daily sGC stimulator vericiguat (compound <b>24</b>, BAY 1021189), currently in phase 3 trials for chronic heart failure, are now reported

Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure

The first-in-class soluble guanylate cyclase (sGC) stimulator riociguat was recently introduced as a novel treatment option for pulmonary hypertension. Despite its outstanding pharmacological profile, application of riociguat in other cardiovascular indications is limited by its short half-life, necessitating a three times daily dosing regimen. In our efforts to further optimize the compound class, we have uncovered interesting structure–activity relationships and were able to decrease oxidative metabolism significantly. These studies resulting in the discovery of once daily sGC stimulator vericiguat (compound <b>24</b>, BAY 1021189), currently in phase 3 trials for chronic heart failure, are now reported